Fuechtenbusch M, et al. - In this post hoc analysis, researchers assessed weight loss in patients with type 2 diabetes (T2D) receiving once-weekly dulaglutide plus insulin lispro vs daily insulin glargine plus insulin lispro. The achieved targets were more profound with 1.5-mg dulaglutide vs insulin glargine: LSM weight change difference, −3.23 kg; proportion of patients without weight gain, 49.0% vs 19.0%; proportion of patients with weight loss ≥ 3%, 21.7% vs 5.7% or with weight loss ≥ 5%, 10.5% vs 2.4%; proportion of patients with HbA1c < 7% without weight gain, 26.2% vs 7.9%; proportion of patients with HbA1c < 7% and weight loss ≥ 3%, 11.9% vs 1.4%, respectively. No significant alterations were observed in treatment outcomes for these parameters across body mass index categories. Larger proportions of patients with late-stage T2D who needed treatment intensification achieved glycemic control without weight gain or weight loss at lower doses of insulin with once-weekly dulaglutide plus daily prandial insulin vs a basal-bolus insulin regimen—overall and across all three body mass index subgroups.